---
title: "ABBV: Robust pipeline and strategic deals drive growth in immunology, neuroscience, and oncology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299075091.md"
description: "Strong growth in immunology, neuroscience, and oncology is driven by a robust pipeline, strategic acquisitions like Apogee, and innovative combination therapies. Market expansion is expected in atopic dermatitis, asthma, Parkinson’s, and multiple myeloma, with significant near-term catalysts and a focus on operational excellence and policy engagement.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-15T15:59:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299075091.md)
  - [en](https://longbridge.com/en/news/299075091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299075091.md)
generator: "portal-rs"
---

# ABBV: Robust pipeline and strategic deals drive growth in immunology, neuroscience, and oncology

Strong growth in immunology, neuroscience, and oncology is driven by a robust pipeline, strategic acquisitions like Apogee, and innovative combination therapies. Market expansion is expected in atopic dermatitis, asthma, Parkinson’s, and multiple myeloma, with significant near-term catalysts and a focus on operational excellence and policy engagement.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)

## Related News & Research

- [AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline](https://longbridge.com/en/news/299075148.md)
- [AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?](https://longbridge.com/en/news/299532734.md)
- [ADARx Pharmaceuticals Prices IPO Of 21.875 Mln Shares Between $15.00 And $17.00/Share](https://longbridge.com/en/news/299652402.md)
- [AbbVie Completes Acquisition of Apogee Therapeutics | ABBV Stock News](https://longbridge.com/en/news/297915640.md)
- [ABBV: Double-digit revenue growth and raised guidance driven by strong immunology and neuroscience](https://longbridge.com/en/news/294533472.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**